ABSTRACT: B cell dysfunction is a well-studied complication of HIV infection in adults. Data on B cell differentiation in normal and HIV-infected children are lacking. We show the distribution of B cell subsets and immunoglobulin levels in HIV-infected children compared with controls. Furthermore, we observe the long-term B cell reconstitution of vaccine-specific immunity after antiretroviral therapy (ART). Phenotype of B cells (naive, non-switched memory, switched memory) was analyzed in 48 infected children and 62 controls. In nine HIV-infected children, functional reconstitution was quantified by tetanus-specific antibodies and by performing a lymphocyte transformation test (LTT) in a longitudinal approach. 
H IV-1 infection leads to a profound impairment of both of the cellular and humoral arm of the immune system. Several abnormalities have been reported in the B cell compartment. Hyperactivation of B cells is thought to result in increased levels of serum immunoglobulins and spontaneous in vitro antibody secretion in unstimulated lymphocyte cultures (1, 2) . Both polyclonal and HIV-specific antibodies are observed (3) . Increased B cell activation markers have been seen; the imbalance of B cell homeostasis is associated with an increased rate of EBV-associated B cell lymphoma (4, 5) . Further dysfunction results from an impaired memory B cell function. A decrease of memory B cells has been reported in adults (6, 7) , as well as an altered vaccine response with recall antigen and stimulation with mitogens (8, 9) . In children, few studies have been made in the B cell compartment. Although they are not yet fully matured in children, B cells are already subject to HIV-induced hyperactivation. Hypergammaglobulinemia is seen in children as well (10) . Some groups observe a reduced total B cell count in HIV-infected children (11, 12) , although these studies were conducted in the pre-antiretroviral therapy (ART) era. The present study compares for the first time HIV-infected with uninfected children regarding detailed B cell differentiation. Further, we investigate the functional reconstitution of the B cell compartment after ART in HIVinfected children regarding the production of vaccine-specific tetanus toxoid antibodies.
METHODS
A total of 48 HIV-infected children (9.36 Ϯ 4.15 y), who were treated at the HIV outpatient clinics of the Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine-University Düsseldorf between 1995 and 2005, were enrolled into the patient cohort for a crosssectional analysis of B cell differentiation. All patients were vertically infected. Children were excluded if data on complete B and T cell differentiation and viral load were not available in at least two different time points. For clinical staging we used the centers for disease control (CDC) classification (13) . In a subgroup of nine infected children, vaccine responses were analyzed for functional B cell reconstitution after ART. Children were included in this cohort if vaccination with diphtheria and tetanus was done before ART and data on lymphocyte transformation test (LTT) and levels of tetanus-specific antibodies were available before and after the initiation of ART.
A total of 62 children (6.03 Ϯ 3.95 y), who underwent elective surgery at the Department of Otolaryngology/Department of Pediatric Surgery at our university, and children in whom various immunologic and rheumatic disorders were ruled out at our department, were taken as controls. Informed consent was obtained from all parents. The Heinrich-Heine University Institutional Review Board approved the study.
Measurement of B cell subpopulations. Within 6 h of whole blood sampling, we performed a three-color cytometry (10,000 Events; FACSCalibur, BD) applying the following Fluorescein-Isothiocyanat (FITC), phycoerythrin (PE), and peridinin chlorophyll protein (PerCP) conjugated antihuman mAbs: CD8ϪFITC, CD4ϪPE, CD3ϪPerCP, IgDϪFITC, CD20ϪPerCP (Becton Dickinson, Bridgeport, NJ) and CD27ϪPE (Immunotech, Marseille Cedex, France). It was gated on B lymphocytes stained with anti-CD20ϪPerCP. CD27 and IgD expression were analyzed among the gated CD20 ϩ population (10,000 Events). IgD ϩ CD27 Ϫ were classified as naive, IgD ϩ CD27 ϩ as non-switched memory, and IgD Ϫ CD27 ϩ as switched memory B cells. A representative facial action coding system (FACS) analysis of B cell differentiation is supplemented (Fig. S1 , Supplemental Digital Content 1, http://links.lww.com/PDR/A44).
Primary immunization schedule. HIV-infected children were immunized according to the German vaccination schedule (14) , which includes diphtheria, tetanus, and pertussis vaccine administered at 2, 3, 4, and 11-14 mo of age, with two booster doses at 5-6 y of age and every 10 y afterward.
Lymphocyte transformation test. In a subgroup of nine HIV-infected patients, we investigated functional reconstitution after ART. We focused on the mitogen response to phytohemagglutinin (PHA), anti-CD3 MAb (OKT3), pokeweed mitogen (PWM), Staphylococcus A Cowan I (SAC) and assessed the antigen-specific cellular response to stimulation with tetanus toxoid. LTT was performed as published (15) . Cells were incubated in suspension with mitogens and tetanus toxoid for 6 d at 37°C and labeled with 3H-thymidine 18 h before the end of the culture period. The incorporation rate of thymidine was measured in counts per minute (cpm) in a Packard Tri-Carb Liquid Scintillation Counter. Proliferation was expressed as a stimulation index (SI) ϭ mean counts of stimulated cultures/mean counts of medium control. Patients were observed at three stages-time point (tp1) children were drug naive when they obtained complete immunization against tetanus. Before initiation of ART (12.5 Ϯ 3 mo after immunization) mitogens and tetanus toxoid-specific LTT were done and tetanus-specific antibodies were determined; (tp2) within 36 Ϯ 20 mo after initiation of ART another series of LTT with mitogens/tetanus antibody detection was done. LTT with tetanus toxoid was available in three patients; (tp3) within 84 Ϯ 15 mo after initiation of ART, children were boostered with tetanus vaccine and a third LTT series (tetanus toxoid and mitogens) with detection of tetanus-specific antibodies was performed.
Measurement of serum immunoglobulins, tetanus-specific antibodies and viral load. Plasma levels of IgG, IgA, and IgM were determined by immunonephelometry and standardized according to reference data (16) . Five children were excluded because of missing immunoglobulin data. Tetanus antibody levels were detected by ELISA (Progen Biotechnik, Heidelberg, Germany). Viral load was determined with quantitative PCR.
Statistical analysis. Absolute CD4 T cell numbers were related to age and age-related percentages (ARP) were calculated as published (17, 18) . Percentages of B cell subpopulations refer to all CD20 gated cells (ϭ all B cells). Data in the text are presented as median and interquartile distance, data related to LTT and tetanus-specific antibodies are presented with mean values and SD. As the age of our cohorts differ significantly (p Ͻ 0.001) two approaches to compare B cell differentiation between HIV-infected children and controls were made (1) by matching 23 individuals from each group by age or (2) by stratifying them to age-related subgroups (2-5 y; 6 -10 y; 11-18 y).
There was no significant difference in viral load between the age-related subgroups (median viral load in all three groups: 10 2 Ϯ 10 3 ; p 1,2 p 2,3 p 1,3 Ͼ0.05). Age-adjusted values were calculated based on the controls. Further, we stratified patients to two subgroups regarding the viral load [Ͻ500 Eq/mL (n ϭ 21) and Ͼ500 Eq/mL (n ϭ 27)]. There was no significant difference in age between these two subgroups, but patient controls were significantly younger than both viral load stratified subgroups in HIV-infected children. Differences were analyzed by t test. p Values Ͻ0.05 were considered statistically significant. Correlation analysis between variables was performed by Microsoft Excel. (Fig. 1) . In addition to age-matched individuals, we compared all patients by stratifying them to age-defined groups to study the ontogenetic influence. Total B cell numbers do not show a significant difference at all, whereas percentages of all B cell subsets and absolute numbers of switched memory B cells show significant changes (decreased switched and nonswitched memory B cells, increased naive B cells; Fig. 2 and Table 1 ).
RESULTS

Memory
The memory B cell depletion is correlated with viral load, but not with clinical stage or CD4 count. HIV-infected children with a viral load Ͼ500 Eq/mL have significantly decreased B cell counts compared with controls (controls 557 Ϯ 468 cells/L, HIVhigh Ͼ500 Eq/mL 308 Ϯ 179 cells/L, pControls/HIVhigh ϭ 0.002). Similarly, we observe significant changes in B cell subsets. Children with a viral load Ͼ500 Eq/mL have significantly decreased switched memory B cells compared with children with a low viral load (controls 42 Ϯ 35 cells/L, HIV Ͻ500 Eq/mL 23 Ϯ 40 cells/L, HIV Ͼ500 Eq/mL: 12 Ϯ 9 cells/L, pControls/HIVlow ϭ 0.011, pHIVhigh/HIVlow ϭ 0.012, pControls/HIVhigh Ͻ0.0001, see Fig. 3 ). Control patients were significantly younger than both subgroups stratified by viral load, but we observe higher switched memory B cells in our control patients compared with HIV-infected children. As switched memory B cells usually increase with age, the difference in age between the groups is, therefore, an unlikely explanation for the reduction of switched memory B cells. To investigate a clinical or immunologic association with B cell differentiation we applied CDC classification for clinical staging. No significant change is noticed between any of the clinical or immunologic 3 cpm; tp2: (7 Ϯ 9) ϫ 10 3 cpm; tp3: (7 Ϯ 7) ϫ 10 3 cpm; SI seen in Table 3 ] decreased slightly, whereas response on OKT3 stimulation increased [tp1: (41 Ϯ 26) ϫ 10 3 cpm; tp2: (46 Ϯ 32) ϫ 10 3 cpm; tp3: (60 Ϯ 24) ϫ 10 3 cpm] (Fig. 5) .
In terms of tetanus toxoid-specific recall antigen, there was no specific response before initiation of ART, despite a history of complete vaccination (Table 3) . After initiation of ART and a tetanus booster vaccination, all seven patients gained tetanus toxoid-specific proliferation (mean tp3: (14 Ϯ 10) ϫ 10 3 cpm). To exclude that this was the result of a general immune reconstitution a LTT with tetanus toxoid was performed in three patients (Patient no. 1, 4, 5 in Table 3 ) after initiation of ART, but before giving tetanus booster vaccination (tp2). All three patients had significantly lower response on LTT with tetanus toxoid before booster, although CD4 cells had shown a recovery. After booster vaccination, LTT with tetanus toxoid in these patients showed a much improved proliferation (tp1: 0 cpm; tp2: (3 Ϯ 5) ϫ 10 3 cpm; tp3: (18 Ϯ 11) ϫ 10 3 cpm). A correlation of OKT3 response with CD4 cell recovery was not seen (Table S1 , Supplemental Digital Content 4, http://links.lww.com/PDR/A47). Antibody response to routine tetanus toxoid immunization was measured before initiation of ART (tp1). After initiation of ART (tp2), five of nine children already had increasing titers of antibodies without booster vaccine (p ϭ 0.07; Table 3 ). Application of a booster regime (tp3) provided all nine children with a protective immunity to tetanus.
DISCUSSION
B cell dysfunction in HIV-infected children has not been well characterized. In our present study, we investigated B cell numbers, B cell differentiation, the lymphocytic proliferative capacity to respond to B cell mitogens, and the ability to mount an antigen-specific antibody response. The total B cell count declines physiologically in growing children. Kam et al. (19) observed in a Chinese pediatric population the rise of total B cell numbers and percentage in the first year, before declining afterward. We did not find a significant decrease of total B cell numbers in HIV-infected children, although in children with a high viral load a decrease in B cell numbers was observed. Studies conducted on children before the availability of ART showed a reduction of B cells. Shearer et al. (11) observed a decrease of the total B cell count in HIVinfected children Ͼ4 y. Other groups described a significant decrease in absolute numbers, while finding same percentages in patient and control cohorts (12, 20) .
Several mechanisms of B cell depletion in HIV are being discussed. First, the number of B cells might be reduced because of hyperactivation and differentiation to antibody- Proliferation is expressed as a stimulation index (SI) ϭ mean counts of stimulated cultures (counts per min)/mean counts of medium control (counts per min). * Before initiation of ART, after basic immunization against tetanus. † After initiation of ART. ‡ After initiation of ART, after booster vaccination against tetanus. ND, not determined.
secreting plasma cells (2) (3) (4) . Plasma cells lose B cell antigen CD20 and were not counted in our investigation (21, 22) . Second, direct infection of a B cell has been reported, which may lead to destruction of some B cells (23), but probably not to a degree that might lead to a significant numerical decrease. Finally, an increased homing of B lymphocytes to lymphatic tissue is discussed due to an increased expression of homing receptors on lymphocytes (24, 25) . Among B cell subsets HIV-infected children show a significant loss of relative and absolute numbers of switched memory B cells. In adults, a loss of memory B cell function has been reported (6, 7, 26) , but data in children have not been published yet. Insufficient differentiation of naive to memory B cells, terminal differentiation of memory B cells to plasma cells, and apoptosis of memory B cells have been discussed explaining memory B cell loss. CD4 T cell depletion could lead to a decreased rate of differentiation to memory B cells. Unlike in adult studies, we did not find a strong correlation between CD4 and switched memory B cells in HIV-infected children (27) . There was no significant difference between patients with an ARP of CD4 cells Ͻ60% and patients with an ARP Ͼ60%. A decrease in memory B cells could be due to an increased terminal differentiation to plasma cells. An increased CD70 expression (CD27 ligand) on CD4 T cells has been associated with increased plasma cell numbers (28) . In addition, plasmocytosis in bone marrow samples was observed in infected adults (26) . For further evaluation, bone marrow and peripheral blood samples would need to be examined simultaneously. Data in children are missing as bone marrow aspirates are not done routinely in HIV-infected children. Hypergammaglobulinemia for IgG, IgA, IgM in HIV-infected children has been reported (10, 11, 29) . In contrast, we only observed an increased IgG level in HIV-infected children compared with reference values.
Other studies hypothesized an increased apoptosis of memory B cells by showing an increased expression of Fas, as well Fas-Ligand on B cells suggesting an autocrine apoptosis induction as a cause for memory B cell reduction (6,30 -32) .
In our cross-sectional analysis, children with lower viral loads had higher numbers of memory B cells. In contrast, in studies in adults, authors observed only little or no difference at all This may reflect a certain vulnerability of the B cell compartment in children and the long-term consequences of this B cell depletion are presently unknown.
Studies by Moir and coworkers (33) discern the B cell subsets by investigating CD21, CD10, and CD27 expression. Immature/transitional B cells (CD10 ϩ /CD27 Ϫ ) are expanded in HIV viremic patients, especially in CD4-depleted patients (34) . Regarding CD21 expression, CD27 ϩ cells are defined in mature activated (CD21low) and resting memory cells (CD21high). The latter are supposed to represent the true memory B cell compartment (35) . Recently, tissue-like memory B cells (CD20 ϩϩ ,CD27 Ϫ ), which have lost CD27 as the classical memory marker, are meant to be expanded in viremic patients representing hyperactivated B cells (36) . Some authors do not observe a restoration of memory B cells after initiation of ART (7); however, a recent study shows an increase of resting memory B cells after 12 mo of ART (37) .
Memory B cells are only partly recovered compared with healthy individuals, which is consistent with our data.
In our longitudinal studies investigating six randomly selected children (data not shown), we could not find an association between change of viral load and switched memory B cells. Patients with continuously high viral loads were having low memory B cell percentages throughout the observation period. In one patient, switched memory B cell percentages increased with increasing viral load. In two patients after changing the drug regime, the viral load was suppressed going along with falling switched memory B cell percentage. For a better interpretation, longitudinal studies have to be performed prospectively in a larger patient cohort with a uniform treatment regime and clinical status.
To assess memory function in more detail, we extended our investigation on the proliferation capability of lymphocytes. All children had tetanus-specific immunity at an average of 7 y after basic vaccination. Three patients, in whom tetanus toxoid-specific proliferation was measured before booster vaccine, regained specific proliferation indicating an immune reconstitution through effective ART without any booster. Zaccarelli-Filho et al. (38) also observed low levels of vaccine specific antibodies in HIV-infected children, whereas other authors also observed good revaccination results concerning tetanus (39) , measles, mumps, and rubella (40) and other live attenuated vaccines (41) (42) (43) (44) in most children on ART.
Our present study shows that despite ART there is a decreased B cell count with decreased numbers of switchedmemory B cells irrespective of the age group. This B cell defect seems to be less pronounced in effectively treated patients with low viral load. Despite lower switched memory B cell numbers complete immunity against tetanus was reached upon booster vaccination demonstrating effective memory B cell responses. The B cell defect described here may still have profound effects on the overall immunity of the child, e.g. for the immunity against HIV itself.
